Background--A human genetic variant (Ser96Ala) in the sarcoplasmic reticulum (SR) histidine-rich Ca 2+ -binding (HRC) protein has been linked to ventricular arrhythmia and sudden death in dilated cardiomyopathy. However, the precise mechanisms affecting SR function and leading to arrhythmias remain elusive.
D
ilated cardiomyopathy (DCM) is associated with a high incidence of ventricular arrhythmias and increased risk of sudden cardiac death from ventricular tachycardia (VT) and ventricular fibrillation.
1,2 The underlying etiologies are not well defined, but impaired Ca 2+ cycling and increased diastolic sarcoplasmic reticulum (SR) Ca 2+ leak via ryanodine receptor 2 (RyR2) have been implicated as a major etiology in the induction of delayed afterdepolarizations (DADs) leading to deleterious ventricular arrhythmias. 3, 4 This defect has been linked to abnormal regulation of RyR2 by luminal Ca 2+ and regulatory proteins, 5, 6 suggesting that targeting these molecules may constitute potential therapy for the treatment of heart failure and malignant arrhythmias. In this regard, the histidine rich Ca 2+ -binding protein (HRC) has recently emerged as a key regulator of SR Ca 2+ cycling. [7] [8] [9] [10] HRC regulates SR Ca 2+ uptake through a direct interaction with sarcoplasmic reticulum Ca 2+ ATPase 2a and inhibits cardiomyocyte relaxation. 10 In addition, HRC binds to triadin, 11, 12 a member of the SR Ca 2+ release channel complex, 13 suggesting that HRC may also regulate RyR2 function. The functional importance of HRC is highlighted by the identification of a human genetic variant (Ser96Ala) that was linked to life-threatening ventricular arrhythmias and sudden death in a well-characterized cohort of patients with idiopathic DCM. 14 Furthermore, the percentage of homozygous Ala/Ala patients with an implantable cardioverter-defibrillator was almost double that of the Ser/Ala heterozygotes, suggesting a strong dosage effect of this HRC genetic variant on ventricular arrhythmias. Indeed, acute overexpression of the human Ala96 HRC variant in isolated adult rat cardiomyocytes by adenoviral gene transfer resulted in aberrant Ca 2+ transient kinetics and increased frequency of Ca 2+ sparks. 15 Previous genetic studies have confirmed the role of defective cardiomyocyte Ca 2+ handling in the pathogenesis of various inherited arrhythmic syndromes. Support for this notion has been provided by the identification and characterization of human mutations in the RyR2, calsequestrin 2 (CASQ2), and triadin genes, which have been linked to catecholaminergic polymorphic ventricular tachycardia, leading to syncope and sudden cardiac death. The underlying mechanisms involve impaired activity or regulation of the RyR2 channel. [16] [17] [18] [19] The present study addressed the in vivo pathophysiological mechanisms associated with the human HRC variant, which was shown to correlate with life-threatening ventricular arrhythmias in DCM. 14 We chose to express the human HRC, which is considerably different than mouse HRC, 20 in the heart of the null (HRC-KO) background, 8 to examine its function in the absence of the endogenous mouse protein.
Here, we demonstrate that Ala96 HRC altered intracellular Ca 2+ handling and promoted arrhythmogenic events in vitro and in vivo, indicating that this variant serves as a susceptibility factor to life-threatening arrhythmias in DCM carriers.
Methods Generation and Identification of Transgenic Mice Expressing Human HRC
An expression construct was generated containing the cardiacspecific a-myosin heavy chain promoter (a-MHC P , 5.5 kb; a gift from J. Robbins, Children's Hospital, Cincinnati, OH), the human HRC cDNA with the HRC Ser96 or HRC Ala96 mutation (HRC cDNA, 3.94 kb; introduced via PCR), and the human growth hormone polyadenylation signal. Microinjection and identification of transgenic mice were performed as described previously. 9 Transgenic C57/BL6 mice with cardiac-specific expression of the human HRC cDNA carrying either the human Ser96 HRC or Ala96 HRC were mated with the HRC-KO mice (C57/BL6) (HRC-KO model was obtained from Dr Do Han Kim, Gwangju Institute of Science and Technology [GIST] , Gwangju, Republic of Korea). 8 F 1 heterozygous HRC offspring with the HRC mutant transgenes were identified by using PCR methodology and bred with HRC-KO mice to obtain the F 2 generation. The HRC-KO offspring carrying the human HRC variant transgenes were selected to backcross with HRC-KO mice for at least 3 generations before using them for our studies. The handling and maintenance of animals were approved by the ethics committee of the University of Cincinnati. Eight-to 12-week-old mice were used for all studies. The investigation conformed to the "Guide for the Care and Use of Laboratory Animals" of the National Institutes of Health.
Mouse Myocyte Isolation and Measurements of Mechanics and Ca 2+ Kinetics
Isolation of mouse left ventricular myocytes was carried out as described previously. 21 
Quantitative Immunoblotting
Alterations in the levels of total proteins or their phosphorylation status were analyzed from whole heart homogenates through Western blotting. For phosphoproteins, hearts were retrogradely perfused through the aorta with Tyrode's solution at constant flow at 37°C for 2 minutes to wash out blood. Perfusion was then continued with Tyrode's solution with or without 100 nmol/L ISO for 5 minutes before rapid freezing. The Tyrode's solution was supplemented with 20 mmol/L NaF, 0.005 mmol/L okadaic acids, to keep the phosphorylation status of the proteins. Briefly, an appropriate amount of heart homogenate was separated via SDS-PAGE (4% to 12%) and transferred to a nitrocellulose membrane (Bio-Rad). After blocking with 5% nonfat milk, membranes were incubated with primary antibodies, followed by appropriate secondary antibodies. Primary antibodies against various proteins of interest used in this study were as follows: pSer16-PLN, pThr17-PLN, pSer2808-RyR2, and pSer2814-RyR2 (Badrilla), PLN (Upstate Biotechnology), RyR2 (Sigma Aldrich), SR Ca 2+ ATPase 2a, sodium calcium exchanger (NCX), triadin, and GAPDH (Affinity Bioreagents). The horseradish peroxidase-conjugated antimouse or antirabbit secondary antibodies (1:5000) were from Amersham Biosciences. The membranes were developed by using an enhanced chemiluminescence Western blot analysis detection system (Amersham Biosciences). All the protein levels were quantified using AlphaEaseFC software (Alpha Innotech).
Ca

2+ Overlay Assay
Enriched SR membrane fractions were isolated from Ser96 and Ala96 hearts, and different amounts (25, 50 , and 100 lg) of protein were analyzed by using SDS-PAGE. The proteins were transferred to nitrocellulose membranes, and the Ponceau red stain was then washed off the nitrocellulose membrane with TBS buffer. The membrane was incubated in (in mmol/L) imidazole 10, pH 6.8, KCl 60, and MgCl 2 5. Thereafter, the membrane was incubated with 1 lCi of 45 Ca 2+ /mL supplemented with 1 mmol/L CaCl 2 at room temperature for 20 minutes, as described previously. 23, 24 The membrane was rinsed with dH 2 0 and analyzed by use of a Storm 860.
Stains-all Staining
Stains-all is a cationic carbo-cyanine dye that stains Ca 2+ -binding proteins blue or red depending on the conditions. 25 Briefly, 5 to 15 lg of whole heart homogenates from wild-type (WT) (nontransgenic), Ser96 and Ala96 mice were separated via 8% SDS-PAGE, and the gels were washed with 25% isopropanol to remove SDS (5920 minutes). 
ISO-Induced Arrhythmias
Mice were anesthetized using 2.5% Avertin and an equivalent of lead I ECG recording (PowerLab; AD Instruments) was performed as previously described. 26 After stabilization of the preparation, a control ECG was recorded for 5 minutes. This was followed by an intraperitoneal injection of ISO 2 mg/kg body weight (Sigma) and a subsequent recording period of 20 minutes. During this period, ECGs were analyzed for ISO-induced arrhythmias.
Myocardial Ischemia/Reperfusion In Vivo
In vivo myocardial ischemia/reperfusion (I/R) was performed through ligation of the left anterior descending coronary artery (LAD) and release of the ligature, as previously described. 28 The LAD was ligated at 2 mm distal from the tip of the left appendix for a period of 30 minutes, and this was followed by releasing the ligation and closing the chest. Ischemia was confirmed by visual observation (cyanosis) and continuous ECG monitoring, using electrodes placed subcutaneously to record data by the PowerLab system (Australia AD Instruments). At different time points after myocardial infarction (MI), mice were anesthetized with 1.0% to 1.5% isoflurane in O 2 and placed on a heating pad (37°C), and cardiac function was assessed by echocardiography, using a Visualsonic Vevo 770 ultrasound equipped with a 30-MHz transducer applied to the chest wall. Cardiac ventricular dimensions and ejection fraction (EF) were assessed in 2-dimensional mode. Analyses were performed by observers blinded to the genotype of the animals. To monitor ventricular arrhythmias and sudden death after I/R, radio transmitters (EA-F20; Data Science International) for ECG recording were implanted in mice 1 week before MI surgery, and ECGs were recorded continuously for 12 weeks after MI. Co-immunoprecipitation was also performed using anti-HRC antibody and cardiac homogenates (1 mg total protein) of Ser96 and Ala96 HRC mice. 29 The precipitates were analyzed by immunoblotting with anti-HRC and anti-Triadin (TRD) antibodies, as indicated. Immunoprecipitate with anti-IgG PLUS agarose was used as negative control.
Coimmunoprecipitation Studies
Electron Microscopy
Hearts were fixed by perfusion through the left ventricle with 3.5% glutaraldehyde in 0. (total volume 1000 lL). All incubations lasted 60 minutes at 37°C. Samples were run in duplicate, filtered onto glass fiber filters (Whatman GF/B), and washed 3 times with 5 mL of cold water using a Brandel M-24R cell harvester. The filters were placed in scintillation vials, 8 mL of liquid scintillation mixture was added, and the retained radioactivity was measured in a Beckman LS-3801 b-counter. The specific binding was defined as the difference between the binding in the absence (total binding) and presence (nonspecific binding) of 20 lmol/L unlabeled ryanodine. Fitting of data was accomplished with the computer program Origin (version 7.5, Microcal Inc).
Histology and Immunocytochemistry
Hearts of 8-to 10-week-old mice (Ser96 HRC, n=3; Ala96 HRC, n=3) were excised, stored in 10% formalin, and serially sectioned. The presence of macroscopic alterations of the heart was assessed by gross inspection; the heart was weighed to determine the heart/body weight ratio. 
Statistical Analysis
Data were expressed as meanAESEM. Comparisons between the means of 2 groups were performed by unpaired Student's t test. For multiple-groups comparisons, 1-way ANOVA was followed by post-hoc Newman-Keuls tests. Quantitative analysis of protein expression and phosphorylation levels were compared using a 1-or 2-way ANOVA and post-hoc NewmanKeuls tests. A repeated-measures 2-way ANOVA test was followed by a Bonferroni post hoc test to examine the effect of drug application (before versus after) between multiple groups. For the studies on isolated cardiomyocytes, 5 to 12 cells per heart were analyzed. The number of hearts/group (N=3 to 5 hearts per group) is indicated. Data from multiple myocytes (n=5 to 12 myocytes/heart) was averaged and the group means were then compared (Ser96 versus Ala96) using ANOVA/t test, wherever applicable. The Mann-Whitney U test was used to compare absolute premature ventricular complex incidence and Fisher exact test was used to evaluate ventricular tachycardia incidence. Categorical data were expressed as percentages and were compared with use of the Fisher exact test. Values of P<0.05 were considered significant.
Results
Cardiac Expression of Human Ser96 HRC and Ala96 HRC in the Null Background
We generated mice with cardiac-specific expression of the human Ser96 or Ala96 HRC variant in the HRC-KO background to determine their effects in the absence of endogenous mouse HRC. This approach was chosen since there is only 48% amino acid homology between human and mouse. 20 We obtained several lines and chose 2 with similar levels of Ser96 and Ala96 HRC expression as those observed in mouse WT heart for further characterization studies ( Figure  S1 ). Cardiac expression of human Ser96 or Ala96 HRC did not elicit any alterations in Ca 2+ -cycling protein levels, compared with WT hearts ( Figure 1A and 1B) . Importantly, the triadin levels, which were previously shown to increase on overexpression of HRC, 9,15 remained unaltered. This may be due to the controlled HRC expression in transgenic hearts since its levels were similar to WT levels ( Figure S1 ). Histological and electron microscopy examination of papillary muscles revealed normal cardiac structure, and both Ser96 and Ala96 HRC co-localized with SR Ca 2+ ATPase at the Z-line ( Figure 1C and 1D compared with the values in Ser96 cells (Figure 2A through  2D) . Consistent with the contractile parameters, analysis of Ca 2+ transients demonstrated that the Ca 2+ amplitude (Fura-2 ratio, 340/380 nm), measured by peak changes from baseline, was decreased by 36% in Ala96 myocytes ( Figure 2E and 2F). Furthermore, T 80 (time to 80% decay of calcium peak) and s were prolonged by %30% in Ala96 cells, compared with Ser96 ( Figure 2G and 2H) . Thus, the impairment in cellular contractility was associated with attenuated cytosolic Ca 2+ -cycling kinetics in Ala96 myocytes. To examine the effects of b-adrenergic agonists, isolated cardiomyocytes were subjected to maximal ISO (100 nmol/L) stimulation and the contractile parameters and Ca 2+ kinetics were evaluated. ISO stimulation resulted in enhancement of contractile parameters, including AEdL/dt and fractional shortening in both Ser96 and Ala96 myocytes, and the maximally stimulated parameters were similar between the 2 groups ( Figure 2B through 2D) . Similarly, Ca 2+ transient amplitude, T 80 , and s were significantly stimulated in both groups, and the maximally stimulated parameters were not different between Ser96 and Ala96 cardiomyocytes ( Figure 2F through 2H) . Figure 3A ). As summarized in Figure 3B, Figure 3D ).
Increased Ca 2+ Sparks and Waves in Ala96 Myocytes
At the myocyte level, heart failure or RyR2 mutations enhance SR Ca 2+ leak, manifested as increases in Ca 2+ sparks or waves, and this serves as the molecular trigger for arrhythmia. 33 To determine the effect of Ala96 on SR Ca 2+ release, we examined to Ser96 cardiomyocytes (Figure 4A and 4B and Table S1 ). Furthermore, spark amplitude, full width at half maximal amplitude, and full duration at half maximal amplitude were unchanged in the absence or presence of ISO (Table S1) spark-independent leak. 34 Therefore, total SR Ca² + leak was also measured using the tertacaine protocol 4 Figure S2 ). Taken together, these findings suggest that expression of Ala96 HRC enhances the propensity for spontaneous Ca 2+ release from the SR by increasing the activity of the RyR2 channel.
Stress Induced Aftercontractions and DADs in Ala96 Cardiomyocytes
To determine the effects of stress conditions in Ala96 HRC cells, we next measured membrane potentials in cardiomyocytes from Ala96 and Ser96 mice at 5-Hz field stimulation in the presence of 1 lmol/L ISO. Spontaneous aftercontractions occurred in 65% of Ala96 cells within 5 seconds after pacing was stopped, compared with 12% of Ser96 HRC cells ( Figure 5A and 5B). Previous studies suggested that aberrant RyR Ca 2+ release may induce arrhythmias by activation of DADs. 18 To determine whether the mechanism for the arrhythmias elicited by Ala96 HRC is related to DADs, electrical activity was examined under increased frequency of stimulation (5 Hz) in the presence of 1 lmol/L ISO in isolated cardiomyocytes. We compared the action potential duration (APD) of Ser96 and Ala96 cells at 5 Hz and 35°C. No significant differences were detected in the APD90, in the APD50, in the amplitude of AP, and in the resting potential between the 2 groups (Table S2 ). However, in the presence of 1 lmol/L ISO, 70% of the Ala96 cells developed DADs within 2 to 5 seconds after termination of 5-Hz stimulation, compared with 20% of the Ser96 HRC cells ( Figure 5C and 5D). Overall, cellular arrhythmias were significantly more common in Ala96 versus Ser96 cardiomyocytes.
Ala96 Does Not Alter the HRC Ca 2+ -binding Properties but Decreases Its Interaction With Triadin
To determine the mechanisms associated with impaired Ca S2814, but not at S2808, at baseline and after ISO stimulation ( Figure 7A through 7C) . The involvement of CaMKII in phosphorylation of S2814 in RyR2 was further confirmed by the ability of KN93, a CaMKII inhibitor, to prevent phosphorylation at this site. Importantly, KN93 blunted the ISO-induced increase in phosphorylation of S2814 without any effect on phosphorylation of S2808 ( Figure 7C ). We then examined the contribution of RyR2 phosphorylation by CaMKII in the Ala96-induced increases of Ca 2+ sparks and waves, using KN93. Inhibition of CaMKII by KN93 significantly prevented the increases in spark frequency under both basal and ISO stimulation conditions ( Figure 7D ). However, spark frequency remained significantly elevated even in the presence of KN93 (with or without ISO; Figure 7D ), indicating that the aberrant SR Ca 2+ release was partially contributed by the increased CaMKII phosphorylation of RyR. Furthermore, KN93 significantly attenuated the ISO-induced Ca 2+ waves, elicited by Ala96 HRC ( Figure 7E ). These findings reveal an additional regulatory mechanism by the Ala96 HRC variant, impacting S2814 phosphorylation of RyR2 and eliciting arrhythmias through this process.
Ala96 HRC Mice Have an Increased Incidence of Ventricular Ectopy on Catecholamine Challenge
We previously reported that the human HRC genetic variant (Ser96Ala) was associated with fatal arrhythmias in DCM patients. 14 Thus, we subjected the Ala96 HRC mice to catecholaminergic stress to determine whether that would induce cardiac arrhythmias in vivo. To test this, the surface ECG was monitored on intraperitoneal injection of ISO. ISO caused frequent premature ventricular complexes in the form of bigeminy and trigeminy ( Figure 8A ) and episodes of nonsustained ventricular tachycardia in Ala96 mice ( Figure  8B ). Arrhythmias typically began 3 to 5 minutes after catecholamine injection and lasted 20 minutes into recovery. Of 8 Ala96 mice, 4 displayed nonsustained ventricular tachycardia, while none of the Ser96 HRC mice showed nonsustained ventricular tachycardia events ( Figure 8C ). Although all VT events were monomorphic, heart rates never exceeded 1000 bpm, and VT rhythms never deteriorated to ventricular fibrillation. The Ser96 mice showed only benign and expected arrhythmias under stress conditions, such as infrequent atrial premature contractions.
Ala96 HRC Mice Exhibit Arrhythmias Associated With Ventricular Tachycardia After MI
To further examine susceptibility to stress conditions, we subjected Ser96 and Ala96 HRC mice to MI in vivo. Interestingly, we observed a marked difference in reperfusion arrhythmias between these groups (Figure 9 mice exhibited VT (9 episodes total; P<0.05) (Figure 9A and  9B) . Furthermore, Kaplan-Meier survival curves showed increased mortality in Ala96 (60%) compared with Ser96 mice (16%; P<0.05) during the same time period (data not shown). We then examined whether Ala96 HRC would exacerbate ventricular arrhythmogenesis in DCM, as observed in human carriers.
14 Thus, we extended the post-MI follow-up study in Ala96 and Ser96 HRC mice and monitored function and geometry longitudinally, using echocardiography. At 12 weeks, both groups exhibited significant decreases in ejection fraction and increases in left ventricular cavity dilation ( Figure 9C and 9D) . These alterations were similar between Ala96 and Ser96 HRC mice. Analysis of telemetry records at 12 weeks post MI indicated that only the Ala96 mice (3 of 4) exhibited spontaneous and prolonged VT, while none (0 of 4) of the Ser96 mice developed VT ( Figure 9E and 9F). These data suggest that the presence of "leaky" RyR2 channels, associated with Ala96 HRC, increases the risk for fatal ventricular arrhythmias in DCM carriers.
Discussion
In the current study, we demonstrate for the first time that expression of human Ala96 HRC in vivo results in catecholaminergically mediated malignant arrhythmia associated with enhanced SR Ca 2+ leak through the ryanodine receptor. The findings indicate that this is the underlying cause of increased risk for sudden cardiac death in DCM patients with Ala96 HRC. Importantly, they suggest that this and other genetic variants in HRC could lie behind cases of idiopathic sudden cardiac death in the general population in the absence of structural cardiac disease.
"Humanized" Ala96 HRC Mouse Exhibits Catecholaminergic Arrhythmia
In end-stage DCM patients, contractile dysfunction is often associated with malignant arrhythmias constituting a major risk factor for sudden cardiac death. 1 These arrhythmias stem mainly from nonreentry mechanisms, such as early afterdepolarizations and DADs, which are linked to impaired cardiomyocyte Ca 2+ cycling. Interestingly, we observed that human DCM patients with Ser96 HRC were protected from arrhythmias, while Ala96 HRC patients developed fatal arrhythmias. 14 To characterize the underlying mechanisms, we generated humanized HRC mice since there is only 48% homology between human and mouse HRC amino acid sequences. 20 The availability of the HRC-null mouse, 8 Importantly, the Ala96 HRC cardiomyocytes exhibited aftercontractions and arrhythmogenic DADs, when paced in the presence of b-adrenergic stimulation consistent with the occurrence of cardiac arrhythmias in the Ala96 HRC mice in vivo.
The findings in the Ala96 HRC mouse are also supported by previous studies, which showed that virus-mediated overexpression of HRC depressed SR Ca 2+ release, 38 whereas knockdown of HRC stimulated Ca 2+ cycling and increased ryanodine binding in cardiomyocytes. 8, 39 Collectively, these results suggest that HRC normally inhibits RyR2 activity and this inhibition is relieved, when HRC is lost or the function of this protein is compromised by genetic mutations. The inhibitory effects of HRC on RyR2 function appear to be mediated though triadin with which HRC interacts. 35 Therefore, the observed upregulation of RyR2 function in Ala96 myocytes could be due to impaired ability of the mutant HRC protein to appropriately interact with triadin. This hypothesis was supported by our protein-binding experiments, which showed that the Ala96 HRC significantly reduced HRC binding to triadin compared with its Ser96 counterpart ( Figure 6 ), leading to RyR2 channels with abnormally high activity, that is, leaky RyR2 (see schematic representation Figure 10 ). It is interesting to compare the role of HRC to that of the homologous SR Ca 2+ -binding protein CASQ2. In addition to serving as an SR Ca 2+ buffer, CASQ2 regulates RyR2 activity through interaction with triadin (and junctin). 13, 40 Moreover, genetic defects in CASQ2 have been also linked to catecholaminergic polymorphic ventricular tachycardia in human patients. 41 Two of the CSQ mutations were reported to contribute to arrhythmogenesis by impairing interaction of CASQ2 with junctin/triadin in the RyR complex, thereby resulting in impaired regulation of RyR2 by luminal Ca 2+ and enhanced propensity for spontaneous Ca 2+ release and DADs. 18, 42 Thus, the Ser96Ala variant of HRC may act in a similar manner on RyR2 activity, to increase vulnerability to lethal cardiac arrhythmias. Notably, at variance with HRC, CASQ2 binds to and inhibits RyR2 at low rather than high luminal Ca 2+ levels. 40, 43 Inhibition of RyR2 at low luminal Ca 2+ has been shown to contribute to luminal Ca 2+ -dependent deactivation that helps to keep RyR2 closed after each release but expected to wane as the SR is refilled with Ca 2+ . 44, 45 Our present study suggests that inhibition of RyR2 by HRC provides another level of control over SR Ca 2+ release expected to operate at high luminal Ca 2+ , when diastolic Ca 2+ is restored (and especially when it is elevated above normal levels). Interestingly, HRC has been reported to bind to the same KEKE motive on triadin that CASQ2 binds. 35, 46 Thus, Ca 2+ -dependent regulation of the RyR complex shows an unexpected complexity that could contribute to dynamic regulation of RyR2 function during the Ca 2+ release-uptake cycle ( Figure 10 ). , and ryanodine receptor (RyR) in the cardiac sarcoplasmic reticulum (SR) membrane. In Ser96 (S96) HRC heart, CSQ interacts with TRI, resulting in deactivation of the RyR channel at low luminal Ca 2+ concentrations, following SR Ca 2+ release (A). On refilling the SR with Ca 2+ , CSQ inhibition is relieved as CSQ dissociates from the RyR complex; however, binding of HRC prevents the RyR from becoming leaky (B). In Ala96 (A96) HRC hearts, CSQ interactions are similar to Ser96 HRC at both low and high Ca 2+ concentrations; however, the interaction of Ala96 HRC with triadin is impaired (C and D), leading to increased RyR2 leak. RyR leakiness is further amplified via phosphorylation by calmodulin-dependent protein kinase II (D).
TRI
SR
Previous studies have shown that phosphorylation of RyR2 by protein kinase A (2808) or CaMKII (Ser2814) increases SR Ca 2+ leak, although most studies have linked only the CaMKIIdependent phosphorylation of RyR2 with diastolic SR Ca 2+ leak in heart failure (HF). 37, 47 In our study, the alterations of RyR2 function and SR Ca 2+ release in Ala96 HRC myocytes were associated with increased phosphorylation of RyR2 at the CaMKII site S2814 and not at the PKA site S2808. Furthermore, inhibiting CaMKII with K93 partially reduced the increased RyR2 Ca 2+ spark rate, both at baseline and after b-adrenergic stimulation (Figure 7) . These findings on altered interaction of Ala96 HRC with the RyR2 complex coupled with amplified CaMKII phosphorylation of RyR2 and increased Ca 2+ leak may constitute the underlying mechanisms for increased propensity of ventricular arrhythmias in vivo under I/R injury or cardiomyopathy conditions in Ala96 HRC mice (Figure 9) . Importantly, the current observations in transgenics correlate with previous clinical results, which linked the Ala96 HRC variant to life-threatening ventricular arrhythmias and sudden death in DCM carriers. 14 In conclusion, a single nucleotide substitution of Thr286Gly in HRC results in a naturally occurring variant (Ala96) that leads not only to depressed SR Ca 2+ cycling and contractility but also to increased SR Ca 2+ leak during diastole. The induced diastolic leak by hyperactive RyR2 triggers aftercontractions and DADs in cardiomyocytes under stress conditions, which predisposes to increased ventricular tachycardia in the setting of DCM even in the absence of any structural heart disease. These findings establish a pathological link between the Ala96 variant in HRC gene and the clinical phenotype in DCM carriers. Thus, Ala96 HRC appears to be a context-sensitive human variant, which becomes arrhythmogenic in heart failure conditions. The underlying molecular mechanisms of this variant and the susceptibility to malignant arrhythmias may provide new insights to pathways of excitation-contraction coupling, leading to the development of novel clinical interventions.
